BHE Stock Analysis: Benchmark Electronics | NYSE
Electronic Components | NYSE, USA | Market Cap: 2.609m USD | 12M Return: 77.8% | US08160H1014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.4M
EPS Trend: 96.1%
Qual. Beats: -1
Rev. Trend: -52.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Benchmark Electronics (NYSE: BHE) is a global provider of integrated product design, engineering, technology, and manufacturing services for original equipment manufacturers (OEMs) across the Americas, Asia, and Europe. The companys offerings span new product design, prototyping, and engineering; printed circuit board assembly and testing; subsystem and system-level integration; precision metal machining and electromechanical assembly; and full lifecycle support including supply chain management, direct order fulfillment, and aftermarket repair, refurbishment, and remanufacturing services.
BHE serves OEMs in advanced computing and communications, aerospace and defense, industrial, medical, and semiconductor capital equipment, primarily selling through a direct sales force. The company was founded in 1979 and is headquartered in Tempe, Arizona.
The company operates in the Electronic Manufacturing Services (EMS) industry, where contractors handle design, assembly, testing, and after-market support on behalf of OEMs that choose to outsource these functions. EMS providers typically generate revenue on a contract basis tied to OEM production volumes, with margins influenced by product mix, complexity, and exposure to higher-value verticals such as aerospace, defense, and medical devices. BHE has been publicly traded since 1990 and is classified within the Information Technology sector.
- Aerospace and defense segment expansion lifts margin mix
- Semiconductor capital equipment demand accelerates from global fab buildouts
- Medical device manufacturing revenue grows on healthcare spending
| Net Income: 53.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.84 > 1.0 |
| NWC/Revenue: 28.02% < 20% (prev 31.09%; Δ -3.07% < -1%) |
| CFO/TA 0.08 > 3% & CFO 177.0m > Net Income 53.1m |
| Net Debt (58.8m) to EBITDA (143.1m): 0.41 < 3 |
| Current Ratio: 1.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.3m) vs 12m ago 0.23% < -2% |
| Gross Margin: 10.23% > 18% (prev 10.00%; Δ 0.23% > 0.5%) |
| Asset Turnover: 132.8% > 50% (prev 127.5%; Δ 5.30% > 0%) |
| Interest Coverage Ratio: 6.10 > 6 (EBIT TTM 97.1m / Interest Expense TTM 15.9m) |
| A: 0.36 (Total Current Assets 1.58b - Total Current Liabilities 795.3m) / Total Assets 2.21b |
| B: 0.26 (Retained Earnings 584.3m / Total Assets 2.21b) |
| C: 0.05 (EBIT TTM 97.1m / Avg Total Assets 2.12b) |
| D: 1.02 (Book Value of Equity 1.12b / Total Liabilities 1.10b) |
| Altman-Z'' = 4.57 = AA |
| DSRI: 0.76 (Receivables 451.6m/544.3m, Revenue 2.82b/2.59b) |
| GMI: 0.98 (GM 10.00% / 10.23%) |
| AQI: 0.90 (AQ_t 0.13 / AQ_t-1 0.15) |
| SGI: 1.09 (Revenue 2.82b / 2.59b) |
| TATA: -0.06 (NI 53.1m - CFO 177.0m) / TA 2.21b) |
| Beneish M = -3.24 (Cap -4..+1) = AA |
As of August 25, 2026, the stock is trading at USD 71.72 with a total of 370,041 shares traded. Over the past week, the price has changed by -14.79%, over one month by -11.57%, over three months by -19.28% and over the past year by +77.80%.
Current recommended Stop Loss: 66.60 (which is 7.1% or 1.2 ATR below the current price).
Benchmark Electronics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BHE.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 86 | 19.9% |
P/E Trailing = 49.7534
P/E Forward = 14.1443
P/S = 0.9258
P/B = 2.3374
P/EG = 1.328
Revenue TTM = 2.82b USD
EBIT TTM = 97.1m USD
EBITDA TTM = 143.1m USD
Long Term Debt = 177.2m USD (from longTermDebt, last quarter)
Short Term Debt = 3.75m USD (from shortTermDebt, last quarter)
Debt = 373.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 96.3m
Net Debt = 58.8m USD (calculated: Debt 373.6m - CCE 314.8m)
Enterprise Value = 2.67b USD (2.61b + Debt 373.6m - CCE 314.8m)
Interest Coverage Ratio = 6.10 (Ebit TTM 97.1m / Interest Expense TTM 15.9m)
EV/FCF = 21.15x (Enterprise Value 2.67b / FCF TTM 126.1m)
FCF Yield = 4.73% (FCF TTM 126.1m / Enterprise Value 2.67b)
FCF Margin = 4.48% (FCF TTM 126.1m / Revenue TTM 2.82b)
Net Margin = 1.89% (Net Income TTM 53.1m / Revenue TTM 2.82b)
Gross Margin = 10.23% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.53b) / Revenue TTM)
Gross Margin QoQ = 10.37% (prev 10.24%)
Tobins Q-Ratio = 1.20 (Enterprise Value 2.67b / Total Assets 2.21b)
Interest Expense / Debt = 4.26% (Interest Expense 15.9m / Debt 373.6m)
Taxrate = 36.49% (30.5m / 83.7m)
NOPAT = 61.7m (EBIT 97.1m * (1 - 36.49%))
Current Ratio = 1.99 (Total Current Assets 1.58b / Total Current Liabilities 795.3m)
Debt / Equity = 0.33 (Debt 373.6m / totalStockholderEquity, last quarter 1.12b)
Debt / EBITDA = 0.41 (Net Debt 58.8m / EBITDA 143.1m)
Debt / FCF = 0.47 (Net Debt 58.8m / FCF TTM 126.1m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.50% (Net Income 53.1m / Total Assets 2.21b)
RoE = 4.81% (Net Income TTM 53.1m / Total Stockholder Equity 1.11b)
RoCE = 7.57% (EBIT 97.1m / Capital Employed (Equity 1.11b + L.T.Debt 177.2m))
RoIC = 4.81% (NOPAT 61.7m / Invested Capital 1.28b)
WACC = 10.38% (E(2.61b)/V(2.98b) * Re(11.48%) + D(373.6m)/V(2.98b) * Rd(4.26%) * (1-Tc(0.36)))
Discount Rate = 11.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -60.74 | Cagr: -0.07%
[DCF] Terminal Value 71.69% ; FCFF base≈107.0m ; Y1≈122.7m ; Y5≈180.5m
[DCF] Fair Price = 54.01 (EV 2.00b - Net Debt 58.8m = Equity 1.94b / Shares 35.9m; r=10.38% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.08 | EPS CAGR: 6.87% | SUE: -4.0 | # QB: -1
Revenue Correlation: -52.02 | Revenue CAGR: -2.14% | SUE: 2.91 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.79 | Chg30d=+10.23% | Revisions=+50% | Analysts=3
EPS current Year (2026-12-31): EPS=2.94 | Chg30d=+7.03% | Revisions=+50% | GrowthEPS=+22.6% | GrowthRev=+12.9%
EPS next Year (2027-12-31): EPS=3.31 | Chg30d=+6.55% | Revisions=+50% | GrowthEPS=+12.3% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: +75% (up=9, down=0)